Alnylam announces Tuschl II patent claims upheld in Japan Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced that the Japanese Patent Office upheld key claims in the Tuschl II patent in an invalidation trial held in Japan. The invalidation request was made by Bio Think-Tank, a Japanese company.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Alnylam has multiple upcoming positive catalysts, says JMP Securities JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares.
Subscribe for More Information
